Severe hemoperitoneum resulting from restart of letrozole after oocyte retrieval procedure: a case report

Abstract Background In the field of oncofertility, patients with breast cancer are often administered letrozole as an adjuvant drug before and after oocyte retrieval to prevent an increase in circulating estradiol. Case presentation We report a case of abdominal hemorrhage due to an ovarian rupture in a 29-year-old Japanese patient who restarted letrozole 2 days after an oocyte retrieval procedure in which 14 mature oocytes were retrieved. The patient had sought embryo cryopreservation as a fertility preservation option before undergoing treatment for recurrent breast cancer. A day after restarting letrozole treatment, the patient unexpectedly developed severe abdominal pain. Laparoscopic hemostasis was performed to manage the ovarian swelling and hemorrhage. Conclusions The ovaries can be restimulated by restart letrozole after an oocyte retrieval procedure. Therefore, reproductive-medicine practitioners should understand the potential complications of letrozole administration in such cases and take steps to ensure that they are minimized.

Download Full-text

Extending letrozole treatment to 10 years may prevent recurrent breast cancer

Evidence-Based Practice ◽

10.1097/01.ebp.0000541701.83801.fa ◽

2017 ◽

Vol 20 (5) ◽

pp. 4

Author(s):

Richard Thompson ◽

Heather O'Mara ◽

Laurel Neff ◽

Mike Arnold

Keyword(s):

Breast Cancer ◽

Recurrent Breast Cancer ◽

Letrozole Treatment ◽

Recurrent Breast

Download Full-text

ER, PR & HER2 Receptor status in recurrent breast cancer: Its relation to age & time of recurrence

Journal of Surgical Sciences ◽

10.3329/jss.v22i1.44009 ◽

2020 ◽

Vol 22 (1) ◽

pp. 16-20

Author(s):

Abu Khaled Muhammad Iqbal ◽

Nasima Akhter ◽

Hasan Shahrear Ahmed ◽

Md Rassell ◽

AMM Yahia ◽

...

Keyword(s):

Breast Cancer ◽

Treatment Approach ◽

Recurrent Breast Cancer ◽

Breast Cancer Patients ◽

Her2 Receptor ◽

Younger Patients ◽

Receptor Status ◽

Increased Risk ◽

Neoplastic Lesions ◽

Recurrent Breast

Background: Malignant neoplastic lesions of the breast are one of the main causes of cancer death among women. In tumor cells the expression status of Estrogen receptor (ER), progesterone receptor (PR), and c-ERBB2 (HER2/neu) are therapeutically and prognostically important markers affecting the treatment approach, management and prognosis of breast carcinoma. Objective: To explore the relation of receptor status in recurrent breast cancer to age and time of recurrence. Methods: This study was conducted in National Institute of Cancer Research and Hospital (NICRH) and included 81 female patients between 20 to 75 years with recurrent breast cancer. Detection of receptor status of ER +ve/-ve, PR +ve/-ve, Her-2+ve/-ve was based on the immunohistochemistry staining of tissue samples of malignant neoplastic lesions prepared from tissue biopsies of patients with recurrent breast cancer. All the information were recorded through the pre-structured data collection sheet and analyzed. Results: This study showed that most of the recurrent breast cancer patients were Triple negative breast cancer (TNBC) (39.5%) and among them most of them were younger patients. Younger patients with TNBC had increased risk of recurrence. Most of the recurrence occurred within 1-2 years. Conclusion: It can be concluded that the assessment of the expression of these biornarkers in recurrent tumors provides reliable information for the treatment approach of locoregional tumors. Journal of Surgical Sciences (2018) Vol. 22 (1): 16-20

Download Full-text